HB 17, Engrossed 1

A bill to be entitled 1 2 An act relating to developmental disabilities; amending s. 409.912, F.S.; requiring the Agency for Health Care 3 Administration, in coordination with the Agency for 4 5 Persons with Disabilities, to develop a model waiver 6 program to serve children with specified disorders; 7 requiring the Agency for Health Care Administration to seek federal waiver approval and implement the approved 8 waiver subject to availability of funds and certain 9 limitations; authorizing rules; providing an 10 11 appropriation; providing an effective date. 12 Be It Enacted by the Legislature of the State of Florida: 13 14 15 Section 1. Subsection (50) is added to section 409.912, 16 Florida Statutes, to read: Cost-effective purchasing of health care.--The 17 409.912 agency shall purchase goods and services for Medicaid recipients 18 in the most cost-effective manner consistent with the delivery 19 of quality medical care. To ensure that medical services are 20 21 effectively utilized, the agency may, in any case, require a 22 confirmation or second physician's opinion of the correct 23 diagnosis for purposes of authorizing future services under the Medicaid program. This section does not restrict access to 24 25 emergency services or poststabilization care services as defined in 42 C.F.R. part 438.114. Such confirmation or second opinion 26 27 shall be rendered in a manner approved by the agency. The agency 28 shall maximize the use of prepaid per capita and prepaid

Page 1 of 3

CODING: Words stricken are deletions; words underlined are additions.

2005

HB 17, Engrossed 1

29 aggregate fixed-sum basis services when appropriate and other alternative service delivery and reimbursement methodologies, 30 including competitive bidding pursuant to s. 287.057, designed 31 32 to facilitate the cost-effective purchase of a case-managed 33 continuum of care. The agency shall also require providers to minimize the exposure of recipients to the need for acute 34 inpatient, custodial, and other institutional care and the 35 inappropriate or unnecessary use of high-cost services. The 36 agency may mandate prior authorization, drug therapy management, 37 or disease management participation for certain populations of 38 39 Medicaid beneficiaries, certain drug classes, or particular drugs to prevent fraud, abuse, overuse, and possible dangerous 40 drug interactions. The Pharmaceutical and Therapeutics Committee 41 42 shall make recommendations to the agency on drugs for which 43 prior authorization is required. The agency shall inform the Pharmaceutical and Therapeutics Committee of its decisions 44 regarding drugs subject to prior authorization. The agency is 45 authorized to limit the entities it contracts with or enrolls as 46 Medicaid providers by developing a provider network through 47 provider credentialing. The agency may limit its network based 48 49 on the assessment of beneficiary access to care, provider 50 availability, provider quality standards, time and distance 51 standards for access to care, the cultural competence of the provider network, demographic characteristics of Medicaid 52 beneficiaries, practice and provider-to-beneficiary standards, 53 appointment wait times, beneficiary use of services, provider 54 turnover, provider profiling, provider licensure history, 55 56 previous program integrity investigations and findings, peer

Page 2 of 3

CODING: Words stricken are deletions; words underlined are additions.

2005

2005

HB 17, Engrossed 1

review, provider Medicaid policy and billing compliance records, 57 clinical and medical record audits, and other factors. Providers 58 shall not be entitled to enrollment in the Medicaid provider 59 60 network. The agency is authorized to seek federal waivers 61 necessary to implement this policy. The agency shall work with the Agency for Persons 62 (50) with Disabilities to develop a model home and community-based 63 waiver to serve children who are diagnosed with familial 64 65 dysautonomia or Riley-Day syndrome caused by a mutation of the 66 IKBKAP gene on chromosome 9. The agency shall seek federal 67 waiver approval and implement the approved waiver subject to the 68 availability of funds and any limitations provided in the 69 General Appropriations Act. The agency may adopt rules to implement this waiver program. 70 71 Section 2. The sums of \$171,840 from the General Revenue 72 Fund and \$246,160 from the Medical Care Trust Fund are 73 appropriated to the Agency for Health Care Administration for 74 the purpose of implementing this act during the 2005-2006 fiscal 75 year. 76 Section 3. This act shall take effect July 1, 2005.

CODING: Words stricken are deletions; words underlined are additions.